Celldex has potential to have a blockbuster Breast Cancer Drug
Results from a Phase II study for CDX-011 - breast cancer are due for release before the summer. The company also is conducting Phase III and Phase II trial for its Rindopepimut in the treatment of glioblastoma.
2012 has started out with a bang for the biotechs and show no end in sight with so many pending FDA approvals coming in next couple of months. Today we got another FDA approval for VRTX.